An Investigation of Levetiracetam in Alzheimer’s Disease (ILiAD): a double-blind, placebo-controlled, randomised crossover proof of concept study

BACKGROUND: Although Alzheimer’s disease affects around 800,000 people in the UK and costs almost £23 billion per year, currently licenced treatments only offer modest benefit at best. Seizures, which are more common in patients with Alzheimer’s disease than age matched controls, may contribute to t...

Descripción completa

Detalles Bibliográficos
Autores principales: Sen, Arjune, Akinola, Mary, Tai, Xin You, Symmonds, Mkael, Davis Jones, Gabriel, Mura, Sergio, Galloway, Joanne, Hallam, Angela, Chan, Jane Y. C., Koychev, Ivan, Butler, Chris, Geddes, John, Van Der Putt, Rohan, Thompson, Sian, Manohar, Sanjay G., Frangou, Eleni, Love, Sharon, McShane, Rupert, Husain, Masud
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8325256/
https://www.ncbi.nlm.nih.gov/pubmed/34332638
http://dx.doi.org/10.1186/s13063-021-05404-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8325256/
https://www.ncbi.nlm.nih.gov/pubmed/34332638
http://dx.doi.org/10.1186/s13063-021-05404-4

Ejemplares similares